

CLINICAL RELEVANCE OF DRUG INTERACTIONS DETECTED IN HEPATITIS C (GENOTYPE 1) TRIPLE THERAPY TREATMENT PATIENTS

M. Martín Marqués¹, S. Jornet Montaña¹, J. Torrent Pou¹, M.F. Vuelta Arce¹, S. Montoliu Llopis², M. Canela Subirada¹.


¹Hospital Universitari Joan XXIII, Pharmacy Service, Tarragona, Spain.

²Hospital Universitari Joan XXIII, Gastroenterology Service, Tarragona, Spain.

Correspondence to Marta Martín Marqués: martamartin.hj23.ics@gencat.cat

BACKGROUND

Protease inhibitors, i.e., Boceprevir (BOC) and Telaprevir (TLV), are metabolized by CYP3A and they are CYP3A inhibitors. This predisposes them to many drug interactions. The identification and management of potential drug interactions with IP is necessary to optimize the treatment in Hepatitis C patients.



PURPOSE

To describe drug interactions and clinical management in Hepatitis C (genotype 1) patients, at the beginning and during the triple therapy treatment.

MATERIAL AND METHODS

✓ Descriptive study involving:

① The registration of the patient's initial treatment using IP

+

The addition of new drugs throughout the treatment

② A drug-interaction analysis of the different IP-based treatments was conducted.

→ Interactions were classified into four categories:



Category 1: No clinically significant interaction;
Category 2: possible interaction but manageable with dose adjustment or monitoring;
Category 3: Co-administration is not recommended;
Category 4: no classification by lack of data.

RESULTS


47 patients
(54 ±8,5 years)

8 with BOC and 39 with TLV

25 (53%) with advanced fibrosis and 33 (70%) previously treated.

A total of 211 drugs prescribed together with triple therapy.

Average drug dosage was 4,49±2,61, only 3 (6%) patients did not need drug interactions study



Regarding clinical management of interactions:

- ✓ All drugs included in category 1 and 2 were not suspended
- ✓ 8 (89%) from category 3 and 2 (15%) from category 4 were suspended

CONCLUSIONS

- ❖ The study reveals a high number of drug interactions when using IP under HC treatment, but only a low number of these interactions required the drug suspension.
- ❖ Drug interactions categorization aids both clinical management and doctors' decision-making processes.

ACKNOWLEDGEMENTS

1. Hep-druginteractions.org. University of Liverpool. [cited 20-05-14]. Available at: <http://www.hepdruginteractions.org>
2. Thomson Healthcare. Micromedex 2.0: Interactions of drugs. [cited 02-12-13]. Available at: <http://www.micromedexsolutions.com/home/dispatch>

No conflict of interest.

The hospital pharmacist's agenda – patient safety first

20th Congress of EAHP
25 – 27 March 2015, Hamburg, Germany